AI assistant
Coloplast — Capital/Financing Update 2022
May 9, 2022
3358_prs_2022-05-09_a2b254a5-e4ed-4561-a97f-91bdb0d23ca3.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
1
Ostomy Care Continence Care Wound & Skin Care Interventional Urology Voice & Respiratory Care
Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark
Company reg. (CVR) no. 69749917 Company reg. (CVR) no. 69749917
Coloplast announces the establishment of its Euro Medium Term Note programme
NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDI-RECTLY, IN THE UNITED STATES. NOT INTENDED FOR RELEASE, PUBLICATION OR DIS-TRIBUTION, DIRECTLY OR INDIRECTLY, TO ANY PERSON IN ANY JURISDICTION WHERE RELEASE, PUBLICATION OR DISTRIBUTION TO SUCH PERSON IS RESTRICTED BY ANY LAW OR REGULATION APPLICABLE IN SUCH JURISDICTION.
THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR ISSUE OR INVITATION TO PUR-CHASE OR SUBSCRIBE FOR, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES.
Coloplast has today established a Euro Medium Term Note Programme (the "EMTN Programme").
The EMTN Programme provides a framework for issuances of senior unsecured notes up to an aggregate principal amount of EUR 3.5 billion by Coloplast and a newly formed subsidiary, Coloplast Finance B.V. ("Coloplast Finance"). Any notes issued by Coloplast Finance will be unconditionally and irrevocably guaranteed by Coloplast.
The Base Prospectus in respect of the EMTN Programme has been approved by the Danish Financial Supervisory Authority (Finanstilsynet) and is available on Coloplast's website at Bond Investors (coloplast.com). Application will be made for any notes issued under the EMTN Programme to be admitted to trading and official listing on the regulated market of Nasdaq Copenhagen A/S.
Ostomy Care Continence Care Wound & Skin Care Interventional Urology Voice & Respiratory Care
Our mission
Making life easier for people with intimate health care needs
Our values
Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us
Our vision
Setting the global standard for listening and responding
For further information, please contact
Investors and analysts
Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: [email protected]
Aleksandra Dimovska Director, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: [email protected]
Press and media
Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: [email protected]
Address
Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917
Website
www.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.
Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ about 14,000 employees.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2022-05. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
DK-3050 Humlebaek Fax +45 4911 1555 Denmark www.coloplast.com
Coloplast A/S Investor Relations Comp. reg. (CVR). Holtedam 1 Tel. +45 4911 1800 69749917